65100-49-4 Usage
Description
IMIPRAMINE-D3 is a labeled tricyclic antidepressant that is known for being a more potent inhibitor of the norepinephrine transporter than the serotonin transporter. It is a clear, colorless oil with significant applications in various fields due to its chemical properties and inhibitory effects.
Uses
Used in Pharmaceutical Industry:
IMIPRAMINE-D3 is used as a labeled tricyclic antidepressant for its potent inhibitory effects on the norepinephrine transporter, making it a valuable tool in the development and study of antidepressant medications. Its ability to inhibit the norepinephrine transporter more effectively than the serotonin transporter provides insights into the mechanisms of action and potential therapeutic applications in treating depression and related disorders.
Used in Research and Development:
IMIPRAMINE-D3 is used as a research compound for studying the interactions between neurotransmitters and their transporters. Its selective inhibition of the norepinephrine transporter can help researchers understand the role of norepinephrine in mood regulation and the development of novel antidepressant drugs.
Used in Neurochemical Analysis:
IMIPRAMINE-D3 is used as a tracer compound in neurochemical analysis to investigate the function and regulation of neurotransmitter transporters. Its labeled nature allows for the tracking of norepinephrine transporter activity, providing valuable information on the underlying mechanisms of neurotransmission and potential targets for therapeutic intervention.
Used in Drug Testing and Quality Control:
IMIPRAMINE-D3 is used as a reference material in drug testing and quality control processes to ensure the purity, potency, and consistency of antidepressant medications. Its labeled nature allows for accurate measurement and comparison of active ingredients in various pharmaceutical formulations, ensuring the safety and efficacy of these drugs for patients.
Check Digit Verification of cas no
The CAS Registry Mumber 65100-49-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,5,1,0 and 0 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 65100-49:
(7*6)+(6*5)+(5*1)+(4*0)+(3*0)+(2*4)+(1*9)=94
94 % 10 = 4
So 65100-49-4 is a valid CAS Registry Number.
InChI:InChI=1/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3/i1D3
65100-49-4Relevant articles and documents
Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: Opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (S)-fluoxetine, and N-desmethyldiltiazem
Hanson, Kelsey L.,VandenBrink, Brooke M.,Babu, Kantipudi N.,Allen, Kyle E.,Nelson, Wendel L.,Kunze, Kent L.
experimental part, p. 963 - 972 (2011/03/18)
Three secondary amines desipramine (DES), (S)-fluoxetine [(S)-FLX], and N-desmethyldiltiazem (MA) undergo N-hydroxylation to the corresponding secondary hydroxylamines [N-hydroxydesipramine, (S)-N-hydroxyfluoxetine, and N-hydroxy-N-desmethyldiltiazem] by cytochromes P450 2C11, 2C19, and 3A4, respectively. The expected primary amine products, N-desmethyldesipramine, (S)-norfluoxetine, and N,N-didesmethyldiltiazem, are also observed. The formation of metabolic-intermediate (MI) complexes from these substrates and metabolites was examined. In each example, the initial rates of MI complex accumulation followed the order secondary hydroxylamine > secondary amine ? primary amine, suggesting that the primary amine metabolites do not contribute to formation of MI complexes from these secondary amines. Furthermore, the primary amine metabolites, which accumulate in incubations of the secondary amines, inhibit MI complex formation. Mass balance studies provided estimates of the product ratios of N-dealkylation to N-hydroxylation. The ratios were 2.9 (DES-CYP2C11), 3.6 [(S)-FLX-CYP2C19], and 0.8 (MA-CYP3A4), indicating that secondary hydroxylamines are significant metabolites of the P450-mediated metabolism of secondary alkyl amines. Parallel studies with N-methyl-d3-desipramine and CYP2C11 demonstrated significant isotopically sensitive switching from N-demethylation to N-hydroxylation. These findings demonstrate that the major pathway to MI complex formation from these secondary amines arises from N-hydroxylation rather than N-dealkylation and that the primary amines are significant competitive inhibitors of MI complex formation. Copyright
